BIOPHARMA CREDIT PLC

AGM Information • Jun 9, 2022

National Storage Mechanism | Additional information

RNS Number : 3892O

BioPharma Credit PLC

09 June 2022

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF 2022 ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed on a show of hands.

At the Annual General Meeting it was agreed that Resolutions 12, 13, 15 and 16 should be withdrawn.

The proxy votes received in relation to the resolutions put to the meeting were as follows:

Resolutions	Votes For	%	Votes Against	%	Votes at Chairman's Discretion	Votes Withheld1
1: To receive and accept the annual report and financial statements	701,371,930	99.99	13,980	0.01	0	0
2: To approve the Directors' Remuneration Report	701,350,388	99.99	35,522	0.01	0	0
3: To re-elect Harry Hyman as a Director	701,373,910	99.99	12,000	0.01	0	0
4: To re-elect Colin Bond as a Director	701,373,910	99.99	12,000	0.01	0	0
5: To re-elect Duncan Budge as a Director	654,374,400	93.3	47,011,510	6.7	0	0
6: To re-elect Stephanie Léouzon as a Director	701,383,410	99.99	1,000	0.01	0	1,500
7: To re-elect Rolf Soderstrom as a Director	701,384,910	99.99	1,000	0.01	0	0
8: To appoint Ernst & Young LLP as Auditor to the Company	691,330,907	98.57	10,055,003	1.43	0	0
9: To authorise the Directors to determine the remuneration of the Auditor	701,356,907	99.99	29,003	0.01	0	0
10: To approve the Company's dividend payment policy	691,385,910	98.57	10,000,000	1.43	0	0
11: To authorise the allotment of shares by the Company	701,017,002	99.99	67,908	0.01	0	301,000
12: To authorise the allotment of shares by the Company	Resolution Withdrawn
13: To authorise the allotment of shares by the Company	Resolution Withdrawn
14: To authorise the disapplication of pre-emption rights	691,301,812	98.56	10,084,098	1.44	0	0
15: To authorise the disapplication of pre-emption rights	Resolution Withdrawn
16: To authorise the disapplication of pre-emption rights	Resolution Withdrawn
17: To authorise the Company to make market purchases of ordinary shares	701,357,930	99.99	27,980	0.01	0	0
18: To authorise the Company to hold general meetings on 14 clear days' notice	701,355,430	99.99	30,480	0.01	0	0

1.     A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

A copy of resolutions 14, 17 and 18 has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

9 June 2022

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSAFMUEESEDM